Creating a New Paradigm
with Shelf-Stable, Allogeneic Cellular Therapies

Cellphire Therapeutics is a clinical stage biotechnology company developing a portfolio of novel, stabilized, allogeneic, platelet-derived, cellular therapeutics. Benefiting from significant historical and planned funding from the US Government, our therapeutics utilize proprietary process and formulation technologies. Cellphire Therapeutics pipeline focuses on saving lives by bringing novel hemostatic products to patients most in need.

Cellphire has two investigational products in Phase 2 clinical trials, including FPH, a stabilized platelet-derived biologic, and Cryopreserved Platelets (CPP).